WALTHAM, Mass., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it has priced its public offering of 4,000,000 shares of its common stock at a public offering price of $36.75 per share. In addition, the Company has granted the underwriters an option to purchase up to an additional 600,000 shares of its common stock, exercisable for 30 days.
Goldman, Sachs & Co. and BofA Merrill Lynch are acting as joint book-running managers for the offering. Cowen and Company, LLC is acting as lead manager.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 20, 2015. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A preliminary prospectus supplement describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or e-mail at prospectus-ny@gs.com, or BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at dg.prospectus_requests@baml.com.